{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Inclusion Criteria (continued):', '5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <3 times the upper limit of', 'normal (ULN) or serum creatinine <1.5 times the ULN (according to age) at the most recent clinic visit.', '6. Diabetic subjects must have well-controlled disease (defined as HbA1c < 9.0% at most recent clinic', 'visit).', '7. Does not require immediate surgical ophthalmological intervention and is not planning corrective', 'surgery/irradiation during the course of the study.', '8.', 'Women of childbearing potential must have a negative urine pregnancy test at Baseline/Day 1. Subjects', 'who are sexually active with a non-vasectomized male partner must agree to use 2 reliable forms of', 'contraception during the trial and continue for 180 days after the last dose of study drug. One of the', '2 forms of contraception is recommended to be hormonal, such as an oral contraceptive. Hormonal', 'contraception must be in use for at least one full cycle prior to Baseline. Highly effective contraceptive', 'methods (with a failure rate less than 1% per year), when used consistently and correctly, includes', 'implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual', 'abstinence or vasectomized partner.', '9.', 'Male subjects must be surgically sterile or, if sexually active with a female partner of childbearing', 'potential, must agree to use a barrier contraceptive method from Baseline through 180 days after the', 'last dose of study drug.', '10. Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the', 'duration of the study.', '11. Has not received any treatment for TED since Week 24 of the HZNP-TEP-301 study.', 'Exclusion Criteria:', '1.', 'Subjects will be ineligible if, in the opinion of the Investigator, they are unlikely to comply with the', 'study protocol or have a concomitant disease or condition that could interfere with the conduct of the', 'study or potentially put the subject at unacceptable risk.', 'The exclusion criteria (except those related to screening) of protocol HZNP-TEP-301 also apply to this', 'open-label extension study.', 'Dose Regimen/Route of Administration:', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff. Subjects will receive', '8 infusions of teprotumumab (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions) in', 'an open-label fashion.', 'The infusion rate may be reduced and the dose may be interrupted or held based on tolerability (see', 'Section 9.4.6.3.2 for details). The first and second infusions will be administered over approximately 90 minutes', '(but not less than 80 minutes). Subsequent infusions will be administered over approximately 60 minutes (but', 'not less than 50 minutes), providing there are no significant infusion-associated events.', 'Dosage Form and Strength Formulation:', 'Teprotumumab 500 mg will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of', 'teprotumumab will be reconstituted with 10 mL of water for injection. The resulting solution will have an', 'approximate concentration of 50 mg/mL teprotumumab. Reconstituted teprotumumab solution will be further', 'diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration.', 'Doses up to 1800 mg will be administered in a total infusion volume of 100 mL, and those above 1800 mg will', 'be administered in a total infusion volume of 250 mL. To maintain a constant volume in the infusion bags, a', 'volume equal to the volume of teprotumumab to be placed into the infusion bag will be first removed from the', 'infusion bag using a sterile syringe and needle. The appropriate volume of reconstituted drug product solution', \"based on the subject's dose and body weight will be withdrawn and the teprotumumab reconstituted drug\", 'product solution will be diluted with normal saline (0.9% NaCl) in the infusion bag.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 33 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Duration of Treatment and Follow-Up:', 'The duration of the Treatment Period is 24 weeks (6 months), during which 8 infusions of teprotumumab will be', 'administered.', 'Subjects who were proptosis non-responders in Study HZNP-TEP-301 are scheduled to participate in a 6-month', 'Follow-Up Period in this extension study; subjects who relapsed in Study HZNP-TEP-301 and are retreated in', 'this extension study will not participate in the Follow-Up Period.', 'Subjects who complete the study (Month 12 Visit for proptosis non-responders in Study HZNP-TEP-301 and', 'Week 24 Visit for subjects who relapsed during the Follow-up Period in Study HZNP-TEP-301) will be', 'contacted 6 and 12 months after the last visit via phone or email by research staff to enquire if any treatment for', 'TED has been received since last study contact.', 'Criteria for Evaluation:', 'The \"study eye\" (i.e., most severely affected eye) will remain the same as that identified at the Baseline (Day 1)', 'Visit of Study HZNP-TEP-301. Both eyes will be assessed for efficacy but the study eye will be used to assess', 'the primary outcome measure.', 'Efficacy will be assessed by proptosis (measured as exophthalmos evaluation of the Clinical Measures of', 'Severity using a Hertel instrument provided by the Sponsor for consistency in measurement), CAS (7-item', 'scale), diplopia (measured as part of the Clinical Measures of Severity) and Clinical Measures of Severity', '(including motility restriction assessments).', 'Quality of life will be assessed using the GO-QoL questionnaire.', 'Safety will be assessed via AE and concomitant medication use monitoring, immunogenicity testing, physical', 'and ophthalmic examinations, vital signs, clinical safety laboratory evaluations (complete blood count,', 'chemistry (including thyroid panel and HbA1c), and urinalysis), pregnancy testing (if applicable), and', 'electrocardiograms (ECG). The study will also be monitored by a Data Safety Monitoring Board (DSMB).', 'Statistical Analyses:', 'The primary analyses will be conducted on the Intent-to-Treat (ITT) population. All efficacy and safety', 'endpoints will be summarized using descriptive statistics, and summaries will be stratified by the treatment', 'received in HZNP-TEP-301 as well as overall.', 'Study endpoints will be evaluated for all subjects from Baseline to Week 24.', 'Primary Efficacy Endpoint', 'The primary outcome measure is the effect of teprotumumab on the proptosis responder rate at Week 24.', 'Secondary Efficacy Endpoints', 'Secondary efficacy endpoints include the percentage of subjects with a CAS value of 0 or 1 at Week 24, mean', 'change from Baseline to Week 24 in the \"study eye\" proptosis measurement, diplopia responder rate at', 'Week 24, and mean change from Baseline to Week 24 in GO-QoL questionnaire overall score.', 'Exploratory Efficacy Endpoints', 'Week 24 data will be summarized for the overall responder rate, the Clinical Measures of Severity individual', 'response status frequencies, the percentage of responders for each component of the Clinical Measures of', 'Severity, and the overall responder rate stratified by the level of response. Mean changes from Baseline to', 'Week 24 will be summarized for the CAS, the GO-QoL questionnaire VF and A subscale scores, and the', 'motility component of the Clinical Measures of Severity. PK parameters will be summarized.', 'Sample Size Estimate:', 'The sample size is not based on statistical considerations. Subjects who are proptosis non-responders at', 'Week 24 of HZNP-TEP-301 or who were proptosis responders at Week 24 but meet the criteria for re-treatment', 'due to relapse during the Follow-Up Period of HZNP-TEP-301 will be eligible for enrollment.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 34 of 118']\n\n###\n\n", "completion": "END"}